15 December 2023 in Russian Neurosurgical Journal named after Professor A. L. Polenov
The first attempts to use immunotherapy in the treatment of patients with glioblastoma were not successful enough. This failure was associated with the immunological privilege of the brain, such features of the tumor itself as low mutational load and genetic heterogeneity. Research conducted in recent years has clarified the features of the functioning of the immune system in the patients with glioblastoma. Today, one of the leading factors of immunosuppression is systemic lymphopenia, not only of an iatrogenic nature, but also induced by the tumor itself. We have presented a review on this topic with a description of three clinical cases with an assessment of the lymphocyte subpopulation in the peripheral blood and the infiltration of immune system cells into the tumor. Immunotherapy options for this group of patients are also presented, taking into account the particularities of the functioning of the immune system.
22 February 2024 in Pediatrician (St. Petersburg)
Malignant gliomas of CNS are the most wide-spread variant of primary brain tumors characteristic of invasive growth, fast evolution, high resistance to therapy and consequently quick recurrence that causes death of the patients. Taking into consideration peculiar features of these neoplasms an acute need has sprung in neurooncologic community for a search of novel low-invasive methods for the assessment of treatment effectivity and determining the progression rate of the disease. During the last decade a great number of studies exploring various circulating tumor ribonucleic acids in case of astrocytoma have been accomplished. The tumor nucleic acids as well as vesicles expressed by glioma may be discovered in blood and spine fluid. Thus these biomarkers are the most perspective targets for realizing these goals. The review presents tumor ribonucleic acids and exosomes, regulatory signaling pathways within tumor glioma cell causing resistance towards alkalizing chemical preparations and directly participating in recurrence. The most prospective nucleic acids as prognosis biomarkers and response to specific antitumor therapy predictors were determined and the most informative methods of their assessment have been depicted. Possibilities of alkalizing agents effectivity rise by means of nucleic acids expression correction have been discussed.
7 December 2023 in Pediatrician (St. Petersburg)
ВГВасильев Андрей Глебович
+9
The engineering and introduction into clinical practice of innovative methods of therapy patients with malignant tumors over the past two decades has certainly led to a significant increase in survival, which does not imply a “cure”, but the fact that more and more patients will live to the stage of metastasis to the central nervous system. The data obtained during diagnostic magnetic resonance imaging in recent years indicates a tendency to increase the number of cases of secondary brain damage in patients with various oncopathologies. Metastasis in the central nervous system is an actual problem due to the fact that the annual survival rate remains very low even with specific antitumor therapy (20 %). The study of the mechanisms of metastasis in the central nervous system is a key factor in the development of new effective approaches to the treatment of patients with this pathology, and, as a result, will lead to an improvement in the prognosis in this group of patients. Due to the analysis of the scientific literature on this issue, we have formulated and presented a modern understanding of the processes occurring in secondary brain damage. Special attention is devoted to organotropism, the mechanism of escape of metastatic cells from the immune system of the central nervous system and interaction with nerve cells, as well as the features of the extracellular matrix of the metastasis. Promising treatment methods being developed are presented.